Jerini Submits Icatibant NDA; Asks FDA For Priority Review

Priority review would give the company’s hereditary angioedema treatment a user fee date in late April/early May 2008, firm tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet